检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial.

Angela R Branche,Nadine G Rouphael, Cecilia Losada,Lindsey R Baden,Evan J Anderson,Anne F Luetkemeyer,David J Diemert,Patricia L Winokur,Rachel M Presti,Angelica C Kottkamp,Ann R Falsey,Sharon E Frey,Richard Rupp,Martín Bäcker,Richard M Novak,Emmanuel B Walter,Lisa A Jackson,Susan J Little,Lilly C Immergluck,Siham M Mahgoub,Jennifer A Whitaker,Tara M Babu,Paul A Goepfert,Dahlene N Fusco,Robert L Atmar,Christine M Posavad,Antonia Netzl,Derek J Smith,Kalyani Telu,Jinjian Mu,Mat Makowski,Mamodikoe K Makhene,Sonja Crandon,David C Montefiori,Paul C Roberts,John H Beigel

medRxiv : the preprint server for health sciences（2023）

引用 0|浏览47
暂无评分
摘要
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent SARS-CoV-2 mRNA vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wildtype spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.
更多
查看译文
关键词
SARS-CoV-2,Vaccine,Variant
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要